v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating Expenses [Abstract]    
Research and development $ 13,397,977 $ 7,657,321
General and administrative 6,599,759 3,114,781
Total operating expenses 19,997,736 10,772,102
Loss from operations (19,997,736) (10,772,102)
Changes in fair value of warrant liabilities (482,474) 5,035,769
Interest expense (62,745) (69,565)
Interest income 1,047,197 62,498
Other income 626,873 546,627
Total other income 1,128,851 5,575,329
Net loss (18,868,885) (5,196,773)
Other comprehensive income (loss):    
Unrealized loss, change in fair value of available-for-sale securities, net of reclassification adjustment and tax (546,791) (975)
Foreign currency translation gain 137,517 24,792
Total comprehensive loss $ (19,278,159) $ (5,172,956)
Loss per common share attributable to the Company's shareholders    
Basic loss per common share $ (0.35) $ (0.56)
Diluted loss per common share $ (0.35) $ (0.56)
Weighted-average common shares outstanding - basic 53,558,639 9,291,641
Weighted-average common shares outstanding - diluted 53,558,639 9,291,641